Alexandra Gerlach, Associate Editor

The data were presented at the 2025 ASCO Genitourinary Cancers Symposium.

Pharmacists can support patients with treatment education, monitoring, and adherence, helping to overcome challenges posed by cognitive decline.

Data from the phase 2 CABRAMET trial suggests the potential of cabozantinib for treatment of brain metastases from renal cell carcinoma (RCC).

Enfortumab vedotin, trastuzumab deruxtecan, and disitamab vedotin were highlighted at the 2025 ASCO Genitourinary Cancers Symposium.

Panelists at the 2025 ASCO Genitourinary Cancers Symposium discussed challenges and new approaches to treatment.

OPN-6602 is an oral EP300/CBP bromodomain inhibitor that yielded 100% tumor regression as a combination therapy in mouse models.

The combination of the antibody-drug conjugate and PD-1/L1 inhibitor yielded an improved progression-free survival in locally advanced or metastatic urothelial carcinoma.

The data were presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California.

The cancer cells developed their own electrical network similar to neural behavior seen in the brain.

The combination greatly improved progression-free survival and overall survival.

Talazoparib in combination with enzalutamide yielded significant improvements in radiographic progression-free survival and overall survival.

Up to 61% of all non-small cell lung cancer (NSCLC) cases harbor EGFR mutations.

Avacincaptad pegol intravitreal solution is a prescription eye injection used to treat geographic atrophy.

Presence of leptomeningeal disease is associated with poorer treatment outcomes and quality of life for patients with breast cancer.

Rezpegaldesleukin is designed to balance the body’s immune system response through activation of regulatory T-cells.

Vietnam war trauma continues to affect veterans’ health 50 years later.

The therapeutic vaccine could provide patients with a non-surgical alternative to traditional treatment approaches.

The decision offers patients with antimicrobial resistance, who have limited or no treatment options, a new alternative.

The quadruple treatment was active and safe as initial therapy for older patients with transplant-ineligible multiple myeloma.

Ming-Hei Tai, PharmD, BCOP, shares his concerns about the AQUILA trial and use of daratumumab for smoldering multiple myeloma.

The Trop-2-tagreting antibody drug conjugate facilitated improved intracranial penetration with favorable tolerability.

Diabetic macular edema (DME) is the leading cause of new blindness in the US.

The study results build on the “obesity paradox,” which suggests that patients with cancer and obesity have better outcomes.

Prescription stimulant dispensing was greatly impacted by the COVID-19 pandemic and drug shortages.

In the study, 50% of the deaths amongst patients were linked to central nervous system-related causes.

Rising seasonal viruses and emerging concerns emphasize the need for public awareness and prevention.

Expert weighs in on data from the AQUILA trial and Johnson & Johnson's approval request for daratumumab for smoldering multiple myeloma.

Continuous dosing of ribociclib was associated with better tolerability and outcomes.

Digoxen is the active ingredient found in the foxglove plant and is commonly used to treat heart failure.

Children and adults with cancer have differing immune system responses, mutational burdens, and tissue microenvironments.